ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

Robert A. Copeland

Robert Copeland

Robert A. Copeland, Ph.D. is President of Research and Chief Scientific Officer of Epizyme, Inc. His research interest is in the discovery and development of small molecule drugs for cancer treatment. He has contributed to 17 drugs entering human clinical trials and has contributed over 200 publications to the scientific literature.